Widely used:Recently Viewed
Clear All₹154.70
₹1.86
(1.22%)
As on 22-Apr-2025 12:14IST
Value Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹4,975 Cr
P/E Ratio
--
P/B Ratio
-31.69
Industry P/E
34.17
Debt to Equity
0.37
ROE
-121.28 %
ROCE
-112.35 %
Div. Yield
0 %
Book Value
-4.84
EPS
-11.97
CFO
₹-1,637.35 Cr
EBITDA
₹-1,862.78 Cr
Net Profit
₹-1,847.71 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Sun Pharma Adv Resrc
| -22.86 | 4.69 | -12.60 | -53.48 | -17.95 | 2.05 | -10.06 |
|
BSE Healthcare
| -6.36 | 0.40 | -0.66 | 22.86 | 19.05 | 22.87 | 9.80 |
|
BSE Small Cap
| -10.21 | 4.02 | -4.87 | 8.28 | 18.78 | 36.02 | 15.81 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Sun Pharma Adv Resrc
| -34.78 | 37.49 | -27.29 | 45.93 | 23.72 | -17.46 | -62.41 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 706.00 | 6,239.74 | 25.03 | 13.8 | |
| 507.45 | 7,994.04 | -- | 0.11 | |
| 2,206.90 | 9,024.00 | 74.35 | 12.96 | |
| 413.30 | 5,104.65 | 68.45 | 6.24 |
3 min read•By Research Desk
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration,... ophthalmology, dermatology, and Immunology. The company offers Elepsia XR, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension; and Phenobarbital injection for the treatment of neonatal seizures. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. The company was incorporated in 2006 and is based in Mumbai, India. Read more
Incorporated
2006
Chairman
Dilip S Shanghvi
Managing Director
--
Group
Sun Pharma
Headquarters
Vadodara, Gujarat
Website
Looking for more details about Sun Pharma Advanced Research Company Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View Announcements
The total asset value of Sun Pharma Advanced Research Company Ltd stood at ₹ 321 Cr as on 31-Dec-24
The share price of Sun Pharma Advanced Research Company Ltd is ₹154.70 (NSE) and ₹154.45 (BSE) as of 22-Apr-2025 12:14 IST. Sun Pharma Advanced Research Company Ltd has given a return of -17.95% in the last 3 years.
Sun Pharma Advanced Research Company Ltd has a market capitalisation of ₹ 4,975 Cr as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Sun Pharma Advanced Research Company Ltd is -31.69 times as on 22-Apr-2025, a 954% discount to its peers’ median range of 3.71 times.
Since, TTM earnings of Sun Pharma Advanced Research Company Ltd is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Sun Pharma Advanced Research Company Ltd and enter the required number of quantities and click on buy to purchase the shares of Sun Pharma Advanced Research Company Ltd.
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, dermatology, and Immunology. The company offers Elepsia XR, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension; and Phenobarbital injection for the treatment of neonatal seizures. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. The company was incorporated in 2006 and is based in Mumbai, India.
The prominent promoters of Sun Pharma Advanced Research Company Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
SHANGHVI FINANCE PRIVATE LTD |
42.28%
|
|
DILIP.S.SHANGHVI |
19.05%
|
|
ADITYA MEDISALES LIMITED |
1.51%
|
The chairman of the company is Dilip S Shanghvi, and the managing director is .
There is no promoter pledging in Sun Pharma Advanced Research Company Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
9,512
|
|
|
7,653
|
|
|
6,653
|
|
|
5,320
|
| Sun Pharma Advanced Research Company Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-635.1
|
|
Net Margin(%)
|
-577.05
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Sun Pharma Advanced Research Company Ltd was ₹-389 Cr.
